CPHI 2025: Redefining Nutraceuticals
Industry Convergence and Innovation
The line separating pharmaceuticals and nutraceuticals is fading, as highlighted at this year’s CPHI 2025 trade show. Innovations are emerging that enhance both efficacy and delivery formats across these industries.
Expert Perspectives on Quality Standards
During discussions with PharmaLinea, Lubrizol, Sirio, Corbion, and Bioiberica, industry leaders emphasized the growing overlap and raised standards within nutraceuticals.
“They have substantial marketing power and are applying pressure to the supplement industry to develop higher quality and proof of efficacy.”
PharmaLinea’s Approach to Clinical Validation
Matevž Ambrožič, marketing director at PharmaLinea, outlined the company’s ongoing effort to elevate nutraceuticals to pharmaceutical-grade standards through rigorous clinical testing:
“While branded ingredients are increasingly backed by clinical studies, finished-product clinical validation is still rare — and that’s where we focus.”
“We already have several product lines clinically studied at the finished-product level, and a large pipeline of upcoming trials. Our goal is to have our entire portfolio clinically substantiated.”
“That’s our way of adapting to the future that will probably be more pharmaceutical-grade standards — at least for a part of the supplement industry.”
Summary
CPHI 2025 revealed a stronger industry push for nutraceuticals to achieve pharmaceutical-level validation and quality, with clinical studies now central to future innovation.